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Abstract 
Background: Mitral regurgitation is a frequent valvular heart disease affecting around 2.5 % of the population 
with prevalence directly related to aging. Degeneration of mitral valve is broadly considered as a passive ongoing 
pathophysiological process and little is known about its physiological deregulation. The purpose of this study was to 
highlight new biomarkers of mitral regurgitation in order to decipher the underlying pathological mechanism as well 
as to allow the diagnosis and the monitoring of the disease.
Results: Modulation of various blood proteins expression was examined in patients suffering from different grades 
of mitral regurgitation (mild, moderate and severe) compared to healthy controls. To this end, several routine clinical 
assays and the multi analyte profile technology targeting 184 proteins were used. High‑density lipoprotein, apoli‑
poprotein‑A1, haptoglobin and haptoglobin‑α2 chain levels significantly decreased proportionally to the degree of 
mitral regurgitation when compared to controls. High‑density lipoprotein and apolipoprotein‑A1 levels were associ‑
ated with effective regurgitant orifice area and regurgitant volume. Apolipoprotein‑A1 was an independent predictor 
of severe mitral regurgitation. Moreover, with ordinal logistic regression, apolipoprotein‑A1 remained the only inde‑
pendent factor associated with mitral regurgitation. In addition, myxomatous mitral valves were studied by immu‑
nocytochemistry. We observed an increase of LC3, the marker of autophagy, in myxomatous mitral valves compared 
with healthy mitral valves.
Conclusion: These potential biomarkers of mitral regurgitation highlighted different cellular processes that could be 
modified in myxomatous degenerescence: reverse cholesterol transport, antioxidant properties and autophagy.
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Background
Mitral regurgitation (MR) is one of the most frequent 
valvular heart disease affecting around 2.5 % of the popu-
lation with a prevalence directly related to aging [1]. Pri-
mary MR i.e. degenerative disease, rheumatic disease or 
endocarditis, is characterized by an impairment of the 
valvular apparatus whereas secondary (functional) MR 
is mainly due to left ventricular (LV) remodelling. Myx-
omatous degeneration of valve leaflets is characterised 
by an excessive matrix remodelling [2]. It follows leaflet 
enlargement and annular dilatation that impair their nor-
mal functions and lead to valve prolapse and MR [3]. So 
far, myxomatous degeneration was mainly considered 
as a passive mechanism and only a few studies investi-
gated the underlying physiological deregulation. How-
ever, some works have highlighted interesting tracks in 
the understanding of the physiopathological mechanisms 
associated with this disease process. For example, matrix 
remodeling, with structural alteration of elastic fibers and 
collagen, could be explained by the excessive matrix met-
alloproteinase proteins (MMPs) and cathepsins secre-
tion by valvular interstitial cells (VICs) in myxomatous 
mitral valves (MMV) [4]. These VICs can differentiate 
into active myofibroblasts with a significant increase of 
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α-smooth muscle actin (α-SMA) upon TGF-β1 stimula-
tion promoting alterations to the valve matrix architec-
ture [5]. Other proteins like osteocalcin and low-density 
lipoprotein receptor-related protein 5 (Lrp5 receptor), 
a member of LDL family, are also up-regulated indicat-
ing an endochondral ossification process in MMV [6]. 
Moreover, a genetic study showed a specific mutation in 
the filamin-A gene causing MMV in an X-linked form 
of familial cardiac valvular dystrophy [7, 8]. Recently, 
autophagy has been emphasized as a negative mecha-
nism that would contribute to decompensated heart 
failure. Indeed, in hemodynamic stress situation and 
pressure overload, autophagy has been showed to play a 
negative role in the maladaptive cardiomyocytes remod-
elling [9, 10]. It has been demonstrated that autophagy is 
induce in atrial cardiomyocytes with severe mitral and 
tricuspid regurgitation and that it is closely associated 
with the development of myolysis in this disease [11]. 
Therefore, it seems that the implication of autophagy 
becomes increasingly evident in the physiopathology of 
heart failure.
In order to better understand the underlying patho-
logical mechanism of MR as well as to highlight blood 
biomarkers to diagnose and monitor the disease, we 
examined expression of various proteins in the serum 
of patients exhibiting MR compared to healthy controls 
(HC) as well as between the different grades of the dis-
ease i.e. mild, moderate and severe. To achieve this goal, 
we used several routine clinical assays and the multi 
analyte profile (MAP), a multiplex immunoassay target-
ing 184 proteins. Since a growing number of evidences 
indicate that autophagy seems to be an increasingly 
important actor of cardiomyocyte remodelling, we also 
studied its implication in MMV compared to healthy 
mitral valves (HMV).
Results
Demographic and echocardiographic data of MR patients 
and HC
The population consisted of 16 healthy controls (HC) and 
64 patients affected by primary MR (cohort 1). Patients 
with MR were divided into three grades of MR severity 
determined by Doppler echocardiography: mild (EROA: 
10.45 ± 4.1 mm2 and RV: 17.8 ± 8 mL), moderate (EROA: 
22.2  ±  9.3  mm2 and RV: 35.8  ±  22.7  mL) and severe 
(EROA: 56.94  ±  17.8  mm2 and RV: 87.8  ±  14.9  mL). 
Moreover, pulmonary pressure (PP) was also measured. 
These data are represented in Fig. 1 at rest (A) and during 
exercise (B). While EROA remained mostly unchanged 
after exercise, we can notice a slight increase of RV for 
the severe group. In addition, PP was largely increased 
for the three MR groups upon exercise. This is in accord-
ance with several studies including the one of Magne 
et al. showing that pulmonary hypertension during exer-
cise is associated with markedly low 2-year symptom-free 
survival [12]. Other characteristics of the cohort are sum-
marized in Table  1. A significant difference was found 
regarding the percentage of patients with cholesterol-
lowering medication (HC: 12.5 %, mild: 35 %, moderate: 
19 % and severe: 5 %; p = 0.018). Therefore, only for lipid 
assays, patients with cholesterol-lowering medication 
were excluded from the analysis (referred as cohort 2 in 
Table 2).
Routine clinical assays
The different clinical assays are represented in Table  2. 
Inflammatory markers (CRP and MPO) levels were 
measured in plasma of all patients (cohort 1) but no 
differences between groups were detected. BNP level 
was not statistically different between the three MR 
groups. Several lipids were measured in samples from 
patients without cholesterol-lowering medications 
(cohort 2; patients with cholesterol-lowering medication 
were excluded from this analysis). Results are summa-
rized in Table  2. Kruskal–Wallis test showed a signifi-
cant variation of HDL level between the four groups 
of patients: HC (mean: 0.64  ±  0.17  g/L), mild (mean: 
0.71 ± 0.06 g/L), moderate (mean: 0.61 ± 0.12 g/L) and 
severe (mean: 0.52 ± 0.15 g/L) with a p value of 0.01 and 
0.008 for MR groups comparisons. Apo-A1 level was sig-
nificantly lower in moderate and severe MR: HC (mean: 
1.74  ±  0.25), mild MR (mean: 1.77  ±  0.17), moderate 
MR (mean: 1.63 ± 0.21), severe MR (mean: 1.45 ± 0.22) 
(p = 0.002). The lower values of HDL and Apo-A1 levels 
were significantly correlated with the severity of the MR 
(Fig. 2). Levels of these two proteins were statistically dif-
ferent between the HC and the severe MR group (HDL: 
p =  0.02 and Apo-A1: p =  0.009) and between the dif-
ferent grades of MR. HDL level discriminated mild MR 
from moderate MR (p = 0.04) or severe MR (p = 0.007). 
Apo-A1 level appeared significantly reduced in patients 
with severe MR (vs. mild MR, p =  0.001; vs. moderate 
MR, p = 0.04).
Multiplex immunoassays
Human discovery MAP 175+ (Additional file 1) was per-
formed on 20 samples composed of pools of serum from 
HC and MR (mild, moderate and severe) patients (cohort 
1). Pools formation is described in Additional file 2. Con-
centration of 184 proteins was measured on each pool. 
144 proteins were detected and 40 had a concentration 
under the detection limit. 23 proteins were statistically 
differentially expressed between the compared groups (p 
value <0.05) (Table 3).
In order to study interactions between potential MR 
biomarkers, the 23 proteins of MAP and APO-A1 were 
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uploaded in STRING software for network analysis. Note 
that HDL, being a lipid, could not been integrated in the 
analysis. Among these 24 proteins, 18 were connected 
with each other (Fig. 3). These data suggest collaborative 
interactions between these proteins highlighting differ-
ent cellular processes that could be implicated in MR. 
Using Expasy database and Pubmed literature, we found 
that these proteins are implicated in main biological pro-
cesses like lipid homeostasis, coagulation, autophagy and 
migration (Table 4).
Among these different proteins, we confirmed, on all 
individual sera, a decrease of haptoglobin (Hpt) level by 
western blotting analysis. Representative image is showed 
in Fig. 4a. Quantification of bands intensity correspond-
ing to the Hpt precursor by Imagequant TL software 
validates the differential serum level observed by MAP. 
Indeed level of Hpt precursor was significantly reduced 
in severe MR compared to HC (p = 0.02) and mild MR 
(p  =  0.009) (Fig.  4b). Moreover, western blot analysis 
allowed us to quantify the intensities of the others bands 
corresponding to different chains of Haptoglobin (Hpt 
α-1, α-2 and β-chain). It appeared that level of Hpt α-2 
chain was significantly lower in patients suffering from 
severe MR compared to the 3 other groups (p =  0.004 
compared to HC, p =  0.002 compared to mild MR and 
p = 0.024 compared to moderate MR) (Fig. 4c).
Factors associated with MR severity
Linear regression analysis showed that HDL and Apo-
A1 levels (but not Hpt and Hpt α-2) correlated with both 
EROA and RV (Table  5). There was a significant nega-
tive correlation between EROA and the log transforma-
tion of HDL level (r = −0.37, p = 0.04) and of Apo-A1 
level (r = −0.37, p = 0.04). Levels of HDL and Apo-A1 
a
b
Fig. 1 Echocardiographic data. a EROA, RV and PP were measured at rest on mild, moderate and severe MR patients. b EROA, RV and PP were 
then measured during exercise. These graphic representations showed that EROA remained unchanged during exercise for all MR group, that RV is 
slightly increased in severe MR during exercise and that PP was largely increased during exercise compared to the values at rest
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Table 1 Demographic, echocardiographic characteristics and risk factors of MR patients and healthy controls
Data are expressed as the mean ± SD except for sex, echocardiographic data, risk factors where data are expressed in number (per cent)
A: p values between the 4 groups; B: p values between the 3 MR groups
MR mitral regurgitation, HC healthy controls, EROA effective regurgitant orifice area, RV regurgitant volume, PP pulmonary pressure
Variables HC (n = 16) MR severity p values
Mild (n = 23) Moderate (n = 21) Severe (n = 20) A B
Demographic data
 Age, years 59.44 ± 7.54 62.04 ± 10.84 61.23 ± 11.99 60.81 ± 12.85 0.91 0.92
 Male sex, n (%) 8 (50) 10 (43) 12 (57) 16 (80) 0.09 0.05
 Height, m 1.70 ± 0.11 1.72 ± 0.11 1.68 ± 0.08 1.71 ± 0.09 0.80 0.58
 Weight, kg 77.64 ± 19.31 74.45 ± 14.85 69.56 ± 11.69 78.3 ± 13.6 0.35 0.19
 Body mass index, kg/m2 26.36 ± 3.98 24.65 ± 3.91 24.25 ± 2.88 26.33 ± 4.21 0.26 0.22
 Waist circumference, cm 95.73 ± 16.67 96.22 ± 9.91 95.5 ± 11.96 97.56 ± 12.25 0.96 0.86
Echocardiographic data
 EROA, mm2 – 10.46 ± 4.07 22.21 ± 9.26 56.94 ± 17.82 – <0.0001
 RV, ml – 17.77 ± 7.99 35.83 ± 22.72 87.85 ± 14.93 – <0.0001
 PP, mmHg – 22.92 ± 4.53 26.43 ± 12.03 33.22 ± 16.12 – 0.11
Risk factors
 Hypertension, n (%) 1 (6.25) 5 (22) 5 (24) 7 (35) 0.25 0.37
 Diabetes mellitus, n (%) 1 (6.25) 2 (3) 1 (1,5) 0 (0) 0.58 0.39
 Smoker, n (%) 5 (31) 1 (4) 6 (30) 3 (15) 0.05 0.03
Table 2 Routine clinical assays
Data are expressed as the mean ± SD
A: Comparisons between the 4 groups; B: Comparisons between the 3 MR groups
MR mitral regurgitation, HC healthy controls, CRP C-reactive protein, MPO myeloperoxidase, BNP B-type natriuretic peptide, HDL high-density lipoprotein, LDL light-
density lipoprotein, Apo apo-lipoprotein, OLDL oxidized-LDL, ALDL antibody against OLDL
a Cohort 1: whole cohort
b Cohort 2: cohort without cholesterol-lowering medication
Variables HC MR severity p values
Mild Moderate Severe
Cohort 1a (n = 16) (n = 23) (n = 21) (n = 20)
Cohort 2b (n = 14) (n = 10) (n = 16) (n = 19) A B
Inflammatory markers
 CRPa (mg/mL) 2.89 ± 2.69 1.50 ± 2.12 2.35 ± 3.13 1.51 ± 1.20 0.18 0.46
 MPOa (ηg/mL) 32.08 ± 17.71 20.83 ± 6.27 35.06 ± 30.72 41.90 ± 36.12 0.10 0.16
Heart failure markers
 BNPa (pg/mL) – 47.76 ± 35.82 73.35 ± 105.4 54.04 ± 30.83 – 0.72
Lipids
 Total cholesterolb (g/L) 2.12 ± 0.38 2.25 ± 0.20 2.04 ± 0.47 2.07 ± 0.35 0.57 0.37
 HDLb (g/L) 0.64 ± 0.17 0.71 ± 0.06 0.61 ± 0.12 0.52 ± 0.15 0.01 0.008
 LDLb (g/L) 1.48 ± 1.25 1.31 ± 0.17 1.19 ± 0.43 1.24 ± 0.35 0.40 0.37
 Triglyceridesb (g/L) 1.67 ± 1.21 1.12 ± 0.35 1.20 ± 0.48 1.56 ± 0.63 0.31 0.11
 ApoA1b (g/L) 1.74 ± 0.25 1.77 ± 0.17 1.63 ± 0.21 1.45 ± 0.22 0.002 0.002
 ApoBb (g/L) 0.99 ± 0.28 1.00 ± 0.16 0.94 ± 0.31 1.02 ± 0.27 0.75 0.60
 OLDLb (ηg/mL) 281.6 ± 210.2 497.2 ± 663.1 631.3 ± 830 763.2 ± 643.1 0.47 0.52
 ALDLb (UI/L) 390.6 ± 139.9 620.3 ± 401 707.3 ± 371 608.5 ± 402.3 0.31 0.18
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negatively correlated with the RV (r = −0.67, p = 0.001 
and r = −0.60, p = 0.005, respectively). We also under-
scored that BMI and waist circumference correlated with 
RV (Table  5). There was a positive correlation between 
RV and body mass index (BMI) (r = 0.65, p = 0.003) and 
waist circumference (Waist circ.) (r  =  0.45, p  =  0.04). 
Finally, BMI was also positively correlated with EROA 
(r = 0.53, p = 0.006, Table 5). Using multivariable anal-
ysis, after adjustment for age, gender and waist circum-
ference, we found that Apo-A1 level was independently 
associated with severe MR (β  =  6.8  ±  2.7, p  =  0.012). 
In addition, Apo-A1 level remained an independent 
predictor of severe MR even after correction for age, 
gender and BMI (β =  5.1 ±  2.3, p =  0.024). In a simi-
lar model using ordinal logistic regression, Apo-A1 was 
the only independent determinant of the severity of MR 
(β = 6.1 ± 2.2, p = 0.007 after age, gender and waist cir-
cumference adjustment and β = 5.4 ± 2, p = 0.004 after 
age, gender and BMI correction).
Autophagy activity
Activation of autophagy process was measured in 
mitral valves from patients by LC3 immunohistochem-
istry (IHC). Autophagosome formation can be evalu-
ated by studying LC3-II turnover, which correlates with 
autophagosome accumulation [14]. IHC were performed 
on 5 MMV and 5 HMV. Representative images are shown 
in Fig.  5a. The counting of LC3 punctuated structures 
was made on all the surface area of the valve section 
(including the three different layers: atrialis, spongiosa 
and fibrosa). As shown in Fig. 5b, the incidence of LC3-II 
in mitral valve was largely increase in MMV compared to 
HMV (1 ± 0.48 vs 3.29 ± 1.55; p = 0.007).
Discussion
Whereas MR is a common valvular heart disease with 
an increased prevalence due to the population aging, lit-
tle is known about its underlying physiological deregula-
tion. This study aims to highlight underlying pathological 
mechanisms of MR as well as blood biomarkers reflect-
ing the grade of the disease and allowing its diagnosis 
and monitoring. To this end, we compared blood pro-
tein level variations from patients suffering from MR to 
HC. Moreover, MR was classified as mild, moderate and 
severe (according to EROA and RV) (Fig. 1) allowing us 
to evaluate protein level variations between different 
grading of the disease. To do this, we used several routine 
clinical assays and the multi MAP technology. As the role 
of autophagy becomes increasingly evident in the physi-
opathology of heart failure, we also investigated its activ-
ity in MMV compared to HMV.
Because inflammation contributes to atherosclerosis 
generation, inflammatory biomarkers such as CRP and 
MPO are usually used to diagnose and assess the prog-
nosis of coronary artery disease [15–18]. Therefore the 
potential modification of these biomarkers was inves-
tigated in patients with MR. CRP and MPO levels were 
not statistically different between patients with MR and 
a b
Fig. 2 HDL and Apo‑A1 levels analysis. a Graphic representation of HDL levels in HC, mild MR, moderate MR and severe MR. HDL levels were 
decreased in severe MR compared to HC (p = 0.02) and compared to mild MR (p = 0.007). HDL levels were also reduced in moderate MR compared 
to mild MR (p = 0.04). b Graphic representation of Apo‑A1 levels in HC and the 3 MR groups. Apo‑A1 levels were significantly reduced in severe MR 
compared to moderate MR (p = 0.04), mild MR (p = 0.001) and HC (p = 0.009). HDL and Apo‑A1 levels were measured using enzymatic colorimet‑
ric test and nephelometry respectively on all individual samples
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HC, suggesting that inflammatory process is weak in pri-
mary MR pathology (Table  2). BNP is also widely used 
for the diagnosis and monitoring of various cardiovas-
cular diseases. It allows appreciating cardiac dysfunc-
tion, which follows left ventricular remodelling [19]. BNP 
was measured only in MR blood samples and no differ-
ence was detected according to MR degree as previously 
reported (Table  2). These data are consistent with the 
study of Detaint et al., highlighting BNP as an emerging 
biomarker of the MR consequences but not of the MR 
degree itself [20]. However, as shown in Table 3, NT-pro-
BNP was increased in all MR groups compared to HC 
exhibiting a decrease in cardiac function.
Lipid metabolism deregulation is well known to play a 
major role in coronary artery disease and in aortic ste-
nosis [21, 22]. In our study, lipid profile was analysed in 
patients with MR and HC (Table 2). There was no change 
in the level of total cholesterol, LDL, Triglyceride, Apo-
B, OLDL and ALDL. However, HDL and Apo-A1 were 
significantly lower in MR compared to HC. Interestingly, 
levels of HDL and Apo-A1 decreased according to the 
severity of MR (Fig.  2). Moreover, these two biomark-
ers gave complementary results. Indeed, HDL allowed 
discriminating mild from moderate or severe MR while 
Apo-A1 permitted to distinguish patients with severe 
MR from these with mild and moderate MR. HDL is well 
known to be inversely related to the risk of myocardial 
infarction [23, 24]. Its main role is to reverse cholesterol 
transport from peripheral tissue to the liver. Apo-A1 is 
the major protein component of HDL and participates in 
the reverse cholesterol transport by acting as a cofactor 
for lecithin cholesterol acyltransferase (LCAT) [25]. So, 
deficit in HDL and Apo-A1 levels suggest a deregulation 
in the reverse cholesterol transport in MR patients [26, 
27].
In addition to these 2 biomarkers, MAP technol-
ogy allowed us to bring out 23 potential biomarkers 
whose blood levels differed from MR to HC (Table  3). 
Table 3 Proteins differentially expressed between the four comparisons (HC, mild, moderate and severe MR)
* p < 0.05
** p < 0.01
Accession number Proteins Genes Significant comparisons (p value)
Up regulated proteins in MR
 P15941 Cancer Antigen 15‑3 MUC1 Mild MR vs severe MR (*)
 P80511 EN‑RAGE S100A12 HC vs severe MR (*)
 P16860 NT‑pro‑BNP NPPB HC vs MR (**), HC vs Severe MR (**), HC vs moderate MR (**), HC vs mild 
MR (**)
Down regulated proteins in MR
 P02652 Apolipoprotein A‑II APOA2 HC vs MR (*), HC vs severe MR (*)
 P02654 Apolipoprotein C‑I APOC1 HC vs severe MR (*)
 P02749 Apolipoprotein H APOH HC vs MR (*), HC vs severe MR (*)
 P06732/P12277 Creatin kinase MB CKM/CKB Mild MR vs severe MR (*)
 P16581 E‑selectin SELE HC vs MR (*), HC vs mild MR (*)
 P02671/P02675/P02679 Fibrinogen FGA, FGB, FGG Mild MR vs severe MR (*)
 P00738 Haptoglobin HP Mild MR vs severe MR (*), moderate MR vs severe MR (*)
 P08887 Interleukin‑6 receptor IL6R HC vs moderate MR (*)
 Q14005 Interleukin 16 IL16 HC vs MR (*), HC vs moderate MR (*)
 P03956 Matrix Metalloproteinase‑1 MMP1 HC vs MR (*)
 P09238 Matrix Metalloproteinase‑10 MMP10 HC vs MR (*), HC vs moderate MR (*)
 Q99616 Monocyte Chemotactic Protein 4 CCL13 HC vs MR (*), HC vs severe MR (*)
 Q9HD89 Resistin RETN HC vs MR (*)
 P02743 Serum‑Amyloid‑P‑component APCS HC vs MR (**), HC vs moderate MR (*), HC vs mild MR (*)
 P02787 Serotransferrin TF HC vs MR (*), HC vs moderate MR (*)
 Q99523 Sortilin SORT1 HC vs MR (*)
P07996 Thrombospondin‑1 THBS1 HC vs MR (*), HC vs mild MR (*)
 P05543 Thyroxine‑Binding Globulin SERPINA7 HC vs MR (**), HC vs severe MR (*), HC vs moderate MR (*), HC vs mild MR 
(*)
 P02766 Transthyretin TTR HC vs severe MR (*), moderate MR vs severe MR (*)
 P04004 Vitronectin VTN HC vs severe MR (*)
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Fig. 3 Protein interactions of potential biomarkers. (STRING software version 9.1; confidence score: 0.400 with no added interractors). Among the 
24 differentially expressed proteins associated with MR, 18 were connected with each other suggesting a collaborative interaction between these 
potential biomarkers. APCS serum‑amyloid‑P‑component, APOA1 apolipoprotein A‑I, APOA2 apolipoprotein A‑II, APOC1 apolipoprotein C‑I, APOH 
apolipoprotein H, CCL13 monocyte chemotactic protein 4, FGA fibrinogen alpha‑chain, FGB fibrinogen beta‑chain, FGG fibrinogen gamma‑chain, 
HP haptoglobin; MMP1 matrix metalloproteinase‑1, MMP10 matrix metalloproteinase‑10, SELE E‑selectin, SERPINA7 thyroxine‑binding globulin, TF 
serotransferrin, THBS1 thrombospondin‑1, TTR transthyretin, VTN vitronectin
Table 4 Main functions of confirmed MR biomarkers and their networked proteins
Accession number Proteins Genes Functions
P02647 Apolipoprotein A‑I APOA1 Lipid homeostasis, migration, coagulation, autophagy
P02652 Apolipoprotein A‑II APOA2 Lipid homeostasis, inflammation
P02654 Apolipoprotein C‑I APOC1 Lipid homeostasis
P02749 Apolipoprotein H APOH Lipid homeostasis, coagulation
P16581 E‑selectin SELE Migration, chemotaxis
P02671/P02675/P02679 Fibrinogen FGA, FGB, FGG Coagulation, apoptosis, vasoconstriction
P00738 Haptoglobin HP Coagulation, inflammation, oxidative stress
High density lipoprotein HDL Lipid homeostasis, migration, autophagy, apoptosis
P03956 Matrix metalloproteinase‑1 MMP1 Matrix remodeling, coagulation
P09238 Matrix metalloproteinase‑10 MMP10 Matrix remodeling, migration
Q99616 Monocyte chemotactic protein 4 CCL13 Proliferation, hypoxia
P02743 Serum‑amyloid‑P‑component APCS Interact with DNA and histones, associated with amyloid deposits
P02787 Serotransferrin TF Proliferation, coagulation
P07996 Thrombospondin‑1 THBS1 Migration, proliferation, chemotaxis, apoptosis, autophagy
P05543 Thyroxine‑binding globulin SERPINA7 Coagulation, hormone transport
P02766 Transthyretin TTRs Coagulation, hormone transport, autophagy
P04004 Vitronectin VTN Coagulation, immune response, migration
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By western blotting and on all individual samples, we 
confirmed a significant decrease of Hpt and its α2-chain 
(Hpt-α2) levels in patients with MR (Fig.  4a); these 
proteins discriminated well mild to severe MR (Fig.  4b, 
c). Hpt-α2 also discriminated moderate MR from severe 
MR (Fig. 4c). Hpt is a binding partner of Apo-A1 and is 
associated with accumulation of atherosclerosis lesions 
[28, 29]. It is a plasma α2-glycoprotein synthesized by 
liver during acute phase. By binding to Apo-A1, Hpt pre-
vents damages from hydroxyls radicals and allows Apo-
A1 to conserve its stimulatory activity on the LCAT [30]. 
So, the interaction between Apo-A1 and Hpt is impor-
tant for correctly handling the reverse cholesterol trans-
port. Hpt has also been reported to have anti-oxidant 




Fig. 4 Haptoglobin level analysis. a Representative western blot of Hpt precursor, beta chain, alpha‑2 chain and alpha 1‑chain in HC and MR (mild, 
moderate and severe). b Graphic representation of Hpt precursor levels and statistical significance of comparisons between the four groups. Hpt 
precursor level was decreased in severe MR compared to HC (p = 0.02) and compared to mild MR (p = 0.009). c Graphic representation of Hpt 
alpha‑2 chain levels and statistical significance of comparisons between groups. Hpt alpha‑2 chain level was decreased in severe MR compared to 
HC (p = 0.004), mild MR (p = 0.002) and moderate MR (p = 0.024). Protein amounts of Hpt precursor and Hpt alpha‑2 chain were quantified from 
western blotting using the Imagequant TL software on all individual samples
Table 5 Correlation coefficients for Apo-A1, HDL and clini-
cal variables for MR patients
NS non significant
* p < 0.05; ** p < 0.01
Apo-A1 HDL BMI Waist circ.
EROA −0.37* −0.37* 0.53** NS
RV −0.60** −0.67** 0.65** 0.45*
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a
b
Fig. 5 Autophagy analysis. a Representative IHC analysis of histological sections from HMV (left) and MMV (right) stained with anti‑LC3 antibody. b 
Graphic representation of the LC3 staining relative to the valve area from HMV (n = 5) and MMV (n = 5). The incidence of LC3 puncta in mitral valve 
was largely increased in MMV compared to HMV (1 ± 0.48 vs 3.29 ± 1.55; p = 0.007)
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as an antioxidant by preventing kidney damages. Thus, 
decrease of Hpt level therefore reduces its antioxidant 
capacity. This would be in line with different studies that 
highlighted an alteration of several antioxidant systems 
in mitral valve prolapses [13, 36]. In addition, consist-
ent with our results, a recent proteomic study, based on 
iTRAQ labeling and ESI–MS/MS, showed a decrease in 
Hpt level of patients suffering from moderate and severe 
MR compared to non-MR patients [37]. However, in 
contrary to our study, MR severity was not considered. 
Indeed, as shown in Fig. 4b, c, reduction of Hpt precursor 
and Hpt α-2 chain levels seemed to be correlated to the 
disease severity. These data are also in line with another 
proteomic paper that recently showed a decrease of 
Apo-A1 and Hpt level in patient’s plasma suffering from 
chronic rheumatic stenosis [38].
Although protein level variations of these four pro-
teins seem to correlate with the severity of the regurgi-
tation, after linear regression analysis, only HDL and 
Apo-A1 level variations were associated with EROA and 
RV, which reflect MR severity (Table  5). Also note that 
BMI was correlated with EROA and RV whereas waist 
circumference with RV only. However, using multivari-
ate analysis and after adjustment for several variables, 
only Apo-A1 level was independent predictor of severe 
MR. Moreover, with ordinal logistic regression, Apo-
A1 remained the only independent determinant of MR 
severity.
The decrease of Apo-A1, HDL, Hpt and Hpt-α2 chain 
in MR patient blood mainly showed a deregulation in 
reverse cholesterol transport. These confirmed biomark-
ers were highly networked with other potential biomark-
ers revealed by MAP (Fig. 3). Among them, several were 
also implicated in lipid homeostasis (Apo-A2, Apo-C1, 
Apo-H). Moreover, nine proteins were implicated in 
coagulation (Apo-A1, Apo-H, fibrinogen, Hpt, MMP-1, 
serotransferrin, thyroxine-binding globulin, thansthyre-
tin and vitronectin), six in migration (Apo-A1, E-selectin, 
HDL, MMP-10, thrombospondin-1 and vitronectin) and 
four in autophagy (Apo-A1, HDL, thrombospondin-1 
and transthyretin) (Table 4).
Recently, it has been demonstrated that the induction 
of autophagy occurs in atrial cardiomyocytes with severe 
MR and that it is closely associated with the development 
of myolysis in this disease [11]. Therefore, autophagy 
activity was studied in MMV compared to HMV. The 
counting of LC3 punctuated structures revealed an 
increase of LC3-II in MMV compared to HMV (Fig. 5). 
This demonstrated a substantial activation of autophagy 
in MR patient valves. Although autophagy activation in 
heart diseases has been largely documented, the mech-
anism by which it is activated and its cellular conse-
quences remained uncertain [9, 10]. During mild pressure 
overload or mild ischemia, autophagy activation can be 
a protective mechanism [39, 40]. Indeed, it antagonizes 
cardiac hypertrophy through protein degradation and 
eliminates misfolded proteins in order to maintain home-
ostasis [41]. Therefore, upregulation of autophagy in fail-
ing heart seems to be a protective response against mild 
hemodynamic stress. However, in more severe hemo-
dynamic stress situation, autophagy has been showed 
to facilitate the maladaptive matrix remodelling [9, 10]. 
This has been demonstrated using mice model with a 
reduced activity of autophagy and where stress overload 
induced a lesser level of left ventricle mitral regurgitation 
and remodelling [42]. Inversely, in mice with high level 
of autophagy, pressure overload increases remodelling 
level [42]. Moreover, autophagy is activated in response 
to ROS accumulation [43]. Myxomatous degenerescence 
is mainly due to excessive matrix remodelling inducing 
abnormal accumulation of elastin, collagen and proteo-
glycans with an increase of ROS level [2, 5, 36, 44–46]. 
This could therefore suggest that autophagy is activated 
at the beginning of the physiopathology of MMV in 
response to ROS accumulation and matrix remodelling 
in order to eliminate excessive and toxic molecules. How-
ever, the excessive matrix remodelling found in more 
severe MMV let us think that autophagy is not able to act 
properly and on the contrary could facilitate the mala-
daptive matrix remodelling.
Several signalling pathways have already been identi-
fied to regulate autophagy. Among them, lipid homeo-
stasis seems to play a significant role. Indeed, in human 
and mouse fibroblasts, cholesterol depletion induced 
autophagy activation [47]. The role of lipid metabolism 
in autophagy has also been demonstrated in endothelium 
where HDL inhibited autophagy induced by oxLDL [48]. 
Moreover, in endothelial progenitor cells, HDL activates 
cell proliferation through the PI3K/Akt pathway, which 
is well known to inhibit autophagy [49, 50]. Here, we 
highlighted a deregulation of lipid metabolism and an 
increase autophagy activity in MR patients.
Conclusion
In this work, we underscored a deregulation in cho-
lesterol transport of MR patients with a decrease of 
HDL, Apo-A1 and Hpt blood levels. We also showed 
an increase of autophagy activity in MMV that could 
be related to HDL and Apo-A1 low levels. All these 
results show a potential disruption of lipid metabolism 
and autophagic activity in the MR physiopathology. 
This provides new information in the understanding of 
myxomatous degeneration and offers new insight in the 
development of therapeutic strategies to improve valve 
leak. In addition, these differentially abundant proteins 
could be considered as biomarkers for the diagnosis and 
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the monitoring of the disease. Nevertheless, a validation 
study on a larger cohort is required. The well-established 
cardio-protective nature of HDL and Apo-A1 made 
them targets for cardiovascular therapies aimed to raise 
circulating levels. Currently, no specific drug is used to 
improve valve leak. The only effective treatment is to 
repair or replace the valve. Therefore, the use of a spe-
cific medication against MR is attractive. For example, 
fibrates, niacin or statins can increase HDL circulating 
levels. Moreover, novel class of drug like cholesterol-
ester-transport-protein inhibitors (CETP) or intravenous 
Apo-A1-therapy, up-regulators of endogenous Apo-A1 
production and Apo-A1 mimetic peptides deserve to be 
evaluated for MR treatment.
Methods
Blood sample collection
Blood samples were collected from MR patients and 
healthy controls (HC). They were enrolled from 2009 to 
2012 at the “Centre Hospitalier Universitaire de Liège”. 
Patients were prospectively seen in our Heart Valve 
Clinic and included in the study when inclusion/exclu-
sion criteria were fulfilled. MR groups only comprise 
patients suffering from primary MR. Patients with other 
valvular diseases (i.e. secondary MR, aortic, tricuspid or 
pulmonary stenosis or regurgitation) were excluded from 
the MR group. HC included peoples without valvular 
diseases. A total of 80 serum and plasma samples from 
patients with primary MR and from HC were collected 
into vacutainer tubes at the time of echocardiography 
measurement. Between 30 min and 2 h after collection, 
blood was centrifuged at 3000g for 10  min to collect 
serum and plasma and immediately processed for analy-
sis or aliquoted and frozen at −80 °C until use.
Patients affected by MR were classified into three cate-
gories according to the severity of the pathology [defined 
by the effective regurgitant orifice area (EROA) and 
regurgitant volume (RV) values]: mild (EROA <20 mm2, 
RV <30  mL), moderate (EROA: 20–39  mm2, RV 
30–59  mL), and severe (EROA >40  mm2, RV >60  mL). 
The ethical committee of the University hospital (CHU-
Liège) approved this study and all patients gave their 
written informed consent.
Echocardiographic method
Systolic pulmonary arterial pressure was derived from 
the peak systolic velocity of the tricuspid regurgitant 
jet according to the simplified Bernoulli equation and 
adding 10  mmHg for the right atrial pressure, as previ-
ously validated [12]. Echocardiographic investigations 
were performed with a Vivid 7 or 9 imaging device (GE 
Healthcare, Little Chalfont, UK). All echocardiographic 
parameters were averaged over three cardiac cycles.
The severity of MR was assessed as recommended 
by current guidelines (Lancellotti et  al., EHJ CV imag-
ing, 2013) and using an integrative approach. EROA, a 
marker of the valvular lesion and RV, a marker of volume 
overload, were quantified using the proximal isovelocity 
surface area (PISA) method. Only one physician read all 
echocardiograms.
Routine clinical assays
CRP (C-reactive protein) level was measured using an 
immunoturbidimetric test (Roche Diagnostics, Man-
heim, Germany) (reference values: 1–6  mg/L). MPO 
(myeloperoxidase), OLDL (oxidized-LDL) and ALDL 
(Anti-OLDL) levels were measured with ELISA kit from 
Biomedica (Wien, Austria) and Mercodia (Ippsala, Swe-
den) respectively (reference values: <55 ng/mL; 200–600 
UI/L; <500  ng/mL respectively). Brain natriuretic pep-
tide (BNP) level was measured by an immunofluores-
cence assay (Biosite, Beckman Coulter, San Diego, LA, 
USA). Total cholesterol (reference values: <1.9  g/L); 
HDL (high density lipoprotein) (reference values: 
>0.4  g/L for male and >0.5  g/L for female); LDL (light 
density lipoprotein) (reference values: <1.15  g/L) and 
triglycerides (reference values: <1.5 g/L) were measured 
using enzymatic colorimetric test from Roche diagnos-
tics. Apo (Apolipoprotein) A1 and B were measured by 
nephelometry using antibodies (Siemens, Erlangen, Ger-
many) (reference values: 1.05–2.05  g/L and 0.6–1.3  g/L 
respectively).
Multiplex immunoassay: multi-analyte profile (MAP)
Multi-analyte profile (MAP) technology is a commer-
cially available high-throughput assay from Myriad RBM 
(Austin, Texas, United States). The Human discovery 
MAP175+ consisted of 184 predefined proteins allowing 
covering dozens of different pathways. These 184 proteins 
are listed on Additional file 1. Concentration determina-
tion of these predefined proteins was performed on 20 
pooled serum samples from patients suffering from mild, 
moderate and severe MR and from healthy controls (HC) 
(Additional file 2). MAP technology is based on the clas-
sic capture-sandwich method using capture antibodies 
attached to fluorescently encoded microspheres. Proteins 
concentration was determined by the flow cytometer 
Luminex machine.
Protein interactions analysis
Protein interactions network was built using the soft-
ware STRING version 9.1 (string-db.org/). STRING is 
an online database enabling to predict physical and func-
tional protein–protein interactions based on databases 
and literature. In Fig.  3, the confidence score was set at 
0.400 with no added interactors. Biological functions 
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study of various proteins was made using Expasy data-
base and Pubmed literature.
Western blot analysis of haptoglobin
Equal volumes of each serum sample from HC and MR 
patients (mild, moderate and severe) (n  =  80) were 
loaded on sodium dodecyl sulfate (SDS)-polyacrylamide 
gel. Separated proteins were then transferred on poly-
vinylidene difluoride membranes (PVDF). Membranes 
were blocked in a 5 % milk solution and then incubated 
with the polyclonal anti-Haptoglobin antibody (Abcam, 
Cambridge, UK). After washing, membranes were incu-
bated with the anti-chicken secondary antibody (Abcam). 
The revelation was performed using the enhanced chemi-
luminescence detection reagent (ECL kit, Thermo Scien-
tific, MA, USA). The detected signals were analysed by 
densitometry and the intensity of each band was meas-
ured with the Imagequant TL software (GE Healthcare). 
To normalize protein levels, the value of the band corre-
sponding to each protein level was divided by the band 
intensity of the intergel controls (i.e. the same sample 
loaded twice on each gel).
Tissue collection
P2 segments of posterior leaflets from MMV (n = 5) were 
obtained during valvuloplasty to correct severe mitral 
regurgitation. Normal P2 segments of posterior leaflets 
from HMV (n = 5) were obtained from hearts of donors 
rejected for transplantation. Tissues collection was made 
in collaboration with the Laboratory of Connective Tis-
sue Biology (GIGA-Cancer, ULg) and the Department of 
Cardiovascular and Thoracic Surgery and Human Anat-
omy (CHU Sart-Tilman, ULg) as previously described 
[13]. The protocol was conformed to the principles out-
lined in the Declaration of Helsinki and was approved by 
the Ethics Committee of Liège University Hospital. All 
patients gave their written informed consent.
Immunohistochemistry
Briefly, a 2 mm strip of tissue was cut in the median of the 
P2 leaflet from the free edge to the annulus. The strips 
were fixed in 4 % neutralized paraformaldehyde (Sigma-
Aldrich) for 2 h, dipped in 70 % (v/v) ethanol and embed-
ded in paraffin. Immunohistochemistry was performed 
on valvular tissue sections after dewaxing and citrate 
unmasking using a primary monoclonal antibody against 
LC3 (1/200, Cell signaling). LC3 was revealed with a sec-
ondary biotinylated goat anti-rabbit antibody (1/400, 
Dako) and an HRP/streptavidin solution (Dako). Stain-
ing was revealed with software OlyVIA (Olympus) and 
Quantity One 4.6 (BioRad). The number of LC3 punctu-
ated structures was counted blindly with the ImageJ soft-
ware (NIH) on the complete tissue section of the strips.
Statistical analysis
All data are presented as median  ±  SD or percentage. 
Comparisons between two groups were assessed using 
the nonparametric Mann–Whitney Test. Normality of 
our data was assessed by the Kolmogorov–Smirnov nor-
mality test. All data were normally distributed (p > 0.05) 
excepting HDL, Apo-A1 and RV (p < 0.05). For compari-
sons between more than two groups, one-way ANOVA 
or Kruskal–Wallis test were used as appropriate. Correla-
tions between data were evaluated with linear regressions 
(Pearson or Spearman test as appropriate). For correla-
tion between abnormally and normally distributed val-
ues, abnormally distributed values were transformed in 
logarithm. Logistic regression and ordinal logistic regres-
sion analysis were used to identify independent predic-
tors of severe MR (i.e. vs. both mild and moderate MR) 
and MR grade severity (i.e. mild vs. moderate vs. severe), 
respectively. Age, gender and body mass index (BMI) or 
waist circumference were entered as adjustment vari-
ables in all multivariable models.
For immunohistochemistry, a mean value of LC3 punc-
tuated structures blindly counted using ImageJ software 
(NIH) was established relatively to the total surface of the 
section and expressed as a fold induction relative to the 
control condition (i.e. HMV) taken as 1.
p values <0.05 were considered statistically significant.
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